A research team has developed a diagnostic system that uses artificial intelligence (AI) to accurately identify the type of ...

RA primarily affects the joints, but it can also cause symptoms in other areas of the body, such as the skin. Learn how RA ...

Such cases are common in the growing population of older adults, where the incidence of nonmelanoma skin cancer is high and factors such ... effectively clearing the lesion and avoiding potential ...

Your brain and skin are interconnected—and when a disorder affects both, treatment must involve a multidisciplinary approach.

The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

The generalized erythroderma form presents with skin lesions resembling an exfoliative erythroderma (Bolognia et al., 2008). Bullae may develop but are not always present.

The US FDA has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults with bullous pemphigoid.

Patient remained without skin lesions for three months, and resumed the use of vaccines without live antigens according to the national vaccination calendar. At nine months old, she received acellular ...

This approval marks the eighth disease indication for Dupixent as a new alternative for patients—many of whom are elderly and ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) to treat bullous ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

Sanofi & Regeneron’s Dupixent receives US FDA approval to treat patients with bullous pemphigoid: Paris Saturday, June 21, 2025, 12:00 Hrs [IST] The US Food and Drug Administrat ...